NEW YORK ( TheStreet) -- CHANGE IN RATINGS
American Eagle (AEO) was upgraded at Brean Murray from Hold to Buy. $23 price target. Estimates were also boosted, given drastic changes from the new CEO, Brean Murray said.
Alpha Natural (ANR) was upgraded at Brean Murray from Hold to Buy. Valuation call, based on a $15 price target, Brean Murray said.
Avon (AVP) was downgraded at UBS to Sell from Neutral. $13 price target. Remain cautious after selloff, UBS said.Boeing (BA) was upgraded at Argusto to Buy from Hold. $85 price target. Company will benefit from higher commercial flight demand, and airlines are looking to replace aging fleets, Argusto said. Bank of America (BAC) was downgraded at JMP Securities from Market Perform to Underperform. $5.50 price target. Expect a more strict Volcker rule to be passed, JMP said. Charles River Laboratories International (CRL) was downgraded to Hold at TheStreet Ratings. Citigroup (C) was downgraded at JMP Securities to Underperform from Market Perform. Expect a divided Washington to be a headwind for financial stocks, JMP said. $23 price target. First Horizon (FHN) was upgraded at Guggenheim to Buy. Company can continue to buy back excess capital, Guggenheim said. $10 price target. First Niagara (FNFG) numbers were cut at Guggenheim. Shares are now seen reaching $9. Estimates were also reduced, given lower yields and high exposure to securities and mortgages, Guggenheim said. Neutral rating. Group 1 Automotive (GPI) was upgraded at Sterne Agee from Neutral to Buy. Valuation call, based on a $65 price target, Sterne Agee said. Goldman Sachs (GS) was downgraded at JMP Securities from Outperform to Underperform. $77 price target. See more downside potential for the industry, which is facing multiple headwinds, JMP said. JP Morgan (JPM) was downgraded at JMP Securities from Market Perform to Underperform. $28 price target. Troubles in Europe will continue to weigh on the industry, JMP Securities said. Manpower Group (MAN) was downgraded to Hold at TheStreet Ratings. Morgan Stanley (MS) was downgraded at JMP Securities from Outperform to Underperform. $11 price target. Estimates were also slashed as Greece and other issues should continue to hang over the industry, JMP said. Myriad Genetics (MYGN) was upgraded at Leerink Swann from Market Perform to Outperform. Reimbursement and IP fears appear overdone, Leerink Swann said.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV